Congratulating Moderna and Merck on Positive Phase 3 Melanoma Results / cancer, Eric Lefkofsky, Merck, Moderna, OncoDaily, ...

Health-care companies rose as traders rotated into high-risk areas such as biotechnology. Moderna shares rose 9% as a breakthrough in skin-cancer vaccines, divulged earlier this week, continued to ...

After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the ...

Moderna's 130% day ran on five conditions. We screened the market for stocks like Moderna and found three names, none a ...

Moderna's cancer treatment could treat more than just Melanoma, though the stock's momentum is already stalling. Should you ...

The experimental mRNA vaccine successfully cleared phase 3 clinical trials, the last step necessary before it can be approved ...

The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers ...

Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak ...

Amid rising cancer burden in India, the mRNA custom-made cancer vaccine for melanoma has intriguing potential. ​While typical ...

Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug ...

Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the ...

Early results from final-stage trial of individualised melanoma jab offer hope of more tailor-made cancer treatments ...